The past six months haven’t been great for Sarepta Therapeutics. It just made a new 52-week low of $52, and shareholders have ...

Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European regulators after a ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...

Needham analyst Gil Blum lowered the firm’s price target on Sarepta (SRPT) to $183 from $202 and keeps a Buy rating on the ...

Sarepta Therapeutics said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment.

Oppenheimer analyst Andreas Argyrides lowered the firm’s price target on Sarepta (SRPT) to $184 from $215 and keeps an Outperform rating on the ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by investment analysts at HC Wainwright from a “sell” ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS ...

A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogene moxeparvovec-rokl), the only ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some ...

Scotiabank analyst Louise Chen maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...